Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ardelyx Inc ARDX

Healthcare Biotechnology
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control... see more

Recent & Breaking News (NDAQ:ARDX)

Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

GlobeNewswire November 21, 2023

XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia

GlobeNewswire November 15, 2023

Ardelyx Announces Departure of Board Member

GlobeNewswire November 13, 2023

Ardelyx to Participate at the Jefferies London Healthcare Conference

GlobeNewswire November 10, 2023

Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States

GlobeNewswire November 6, 2023

Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023

GlobeNewswire November 3, 2023

Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance

GlobeNewswire October 31, 2023

Ardelyx, Inc. Reports Employment Inducement Grants

GlobeNewswire October 30, 2023

Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023

GlobeNewswire October 23, 2023

Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023

GlobeNewswire October 18, 2023

Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital

GlobeNewswire October 17, 2023

FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor

GlobeNewswire October 17, 2023

Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA

GlobeNewswire October 13, 2023

Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023

GlobeNewswire October 4, 2023

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

GlobeNewswire September 28, 2023

Tenapanor for Hyperphosphatemia Approved in Japan

GlobeNewswire September 25, 2023

Grabar Law Office Investigates Claims on Behalf of Shareholders of Ardelyx Inc. (ARDX)

Newsfile September 20, 2023

Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023

GlobeNewswire September 11, 2023

Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 8, 2023

Ardelyx, Inc. Reports Employment Inducement Grants

GlobeNewswire September 7, 2023